Arvinas develops protein degrader medicines that aim to remove disease-causing proteins to treat cancer and neurological diseases. It last closed at $6.82 on Nov 17, up 0.74% on the day.
Only 1 firm rated ARVN in the past 90 days, not enough for a consensus
Average 12-month target
$13.00
▲ 90.6% upside
Based on 1 analyst who set a price target on ARVN in the past 90 days. The average target is $13.00, with a high of $13.00 and a low of $13.00, compared with the last close of $6.82.
Low $13.00Avg $13.00High $13.00
Blue marker: last close $6.82
Highest target$13.00
Average target$13.00
Lowest target$13.00
Latest rating changes
HC Wainwright & Co.Maintained
Nov 3Buy$13
Evercore ISI GroupMaintained
Aug 10Buy$14
Wells FargoDowngrade
Aug 5Hold$11
WedbushMaintained
Aug 5Hold$12
BTIGReiterated
Aug 4Buy$18
Date
Firm
Action
Rating
Price target
Nov 3
HC Wainwright & Co.
Maintained
Buy
$13
Aug 10
Evercore ISI Group
Maintained
Buy
$14
Aug 5
Wells Fargo
Downgrade
Hold
$11
Aug 5
Wedbush
Maintained
Hold
$12
Aug 4
BTIG
Reiterated
Buy
$18
Loading…
Technical Analysis
ARVN · as of the Nov 17 close · updated after every close
Downtrend
The stock is 5% below its 20 day and 10% below its 50 day average. It is 37% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 43). The nearest support is the swing low (Oct 14) at $6.74, and the nearest resistance the Pivot R1 at $6.95.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityHigh, 5.7%/day
Key levels
$14.5152 week high+112.8%
$9.33200 day average+36.8%
$8.11100 day average+18.9%
$7.5250 day average+10.3%
$7.1820 day average+5.3%
$6.96Swing high (Nov 11)+2.1%
$6.95Pivot R1+1.9%
$6.82Last close
$6.74Swing low (Oct 14)−1.2%
$6.70Pivot−1.8%
$6.57Pivot S1−3.7%
$6.3352 week low−7.2%
Indicators
RSI (14)
42.63
Middle of its range
Neutral
MACD
-0.23
Below its signal line
Bearish
Stochastic
27.8
Middle of its range
Neutral
ADX (14)
19.7
No clear trend
Williams %R
-71.2
Oversold below −80, overbought above −20
Neutral
CCI (20)
-81.1
Oversold below −100, overbought above 100
Neutral
Rate of change
−3.8%
Change over 10 sessions
Bearish
ATR (14)
$0.39
Typical daily range, 5.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchNormal
VolatilityNormal, 13.4%/day
Key levels
$14.5152 week high+112.8%
$9.33200 day average+36.8%
$8.11100 day average+18.9%
$7.5250 day average+10.3%
$7.1820 day average+5.3%
$6.96Swing high (Nov 11)+2.1%
$6.95Pivot R1+1.9%
$6.82Last close
$6.74Swing low (Oct 14)−1.2%
$6.70Pivot−1.8%
$6.57Pivot S1−3.7%
$6.3352 week low−7.2%
Indicators
RSI (14)
38.31
Weak, oversold below 30
Neutral
MACD
-0.70
Below its signal line
Bearish
Stochastic
9.9
Near the bottom of its range
Oversold
ADX (14)
21.3
Weak trend
Williams %R
-85.6
Oversold below −80, overbought above −20
Oversold
CCI (20)
-128.3
Oversold below −100, overbought above 100
Oversold
Rate of change
−19.3%
Change over 10 sessions
Bearish
ATR (14)
$0.92
Typical daily range, 13.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for ARVN
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how ARVN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow ARVN usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ARVN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ARVN is in one of them and how their past ARVN trades turned out.
Arvinas is a biotechnology company based in New Haven, Connecticut. It develops medicines that use targeted protein degradation, a method that removes disease-causing proteins from cells by using the body's own protein disposal system. Its drug candidates focus mainly on cancer and neurological diseases such as Parkinson's disease, and several are in clinical trials with patients. The company also works with larger drug makers, including Pfizer and Genentech, on early-stage research.